ABSTRACT
. The SNPs were selected because they have been previously shown to be associated 120 with efavirenz plasma concentrations or effect (18, 19, 43) , as well as CYP3A4 and CYP2B6 
Statistical analysis

125
Univariate analyses of association between patient factors and efavirenz AUC 0-24 hour were 126 assessed by t-test or Mann-Whitney rank sum test (sex, race, and history of alcohol use), analysis 127 of variance ANOVA (three genotype groups) or Spearman rank order correlation test (age, body 128 weight and body mass index). Arithmetic means of efavirenz pharmacokinetic parameters the day of PK sampling, we could not rule out medication non-adherence and the individual was 146 excluded from further analysis.
147
The final study population of 11 subjects included 6 Caucasians and 5 African-Americans 148 and 6 females and 5 males. The mean (SD) age was 42.6 (7.5) years, body weight was 76.9 149 (18.9) kilograms, and body mass index (body mass index) was 26.9 (5.7) kg/m 2 . The coefficient 150 of variation (CV) in efavirenz plasma AUC 0-24 h was 50% and 56% in the absence and presence 151 of rifampin, respectively. The distribution of efavirenz plasma AUC weight and efavirenz AUC 0-24 h in the induced sate (correlation coefficient = -0.764; P = 0.005).
161
Age, body mass index, sex, ethnicity and other genetic factors evaluated were not significantly 162 associated with efavirenz AUC 0-24 h in either treatment periods (P > 0.05) (Figure 1 ). 
178
Individual efavirenz AUC 0-24h ratios (on: off rifampin) ranged from 0.55 to 1.18 ( Figure   179 3), with an arithmetic mean (SD) of 0.84 (0.18). There was a trend towards inversely 180 relationship between the AUC 0-24h ratio and body weight (correlation coefficient = -0.591, P = the genetic factors evaluated.
183
The changes in efavirenz AUC 0-24h or weight-normalized CL/F between the two periods 184 appeared to be minimal in a majority of the subjects (Figure 4) . Ten subjects showed a 6 -44% 185 decrease in efavirenz AUC 0-24h with rifampin cotreatment. Two subjects (W1 and W4) had 
188
Three subjects (W001, W004, and B006) had paradoxical decreases in efavirenz CL/F of 24.1,
189
21.1 and 14.0% with rifampin cotreatment compared to when efavirenz was administered alone
190
( Figure 4B ).
191
Factors associated with efavirenz C24h < 1000 ng/mL in the presence of rifampin
192
Five of the 11 subjects had efavirenz C 24h < 1000 ng/mL during rifampin cotreatment, while only lower baseline efavirenz plasma AUC or C 24h were significantly associated with efavirenz C 24h < 198 1000 ng/mL ( Table 2 ). Both subjects with CYP2B6 516/983 fast metabolizer genotypes in the 199 study population had C 24h < 1000 ng/mL and two of the three individuals with slow metabolizer 200 genotypes had C 24h > 4000 ng/mL, which is considered the upper limit of the therapeutic range
201
( Table 2) .
10
Safety and tolerability
203
The administration of efavirenz alone or with rifampin for 8 days was well tolerated in this 204 study. Central nervous system (CNS) side effects of efavirenz were evaluated using the CNS The findings of this study indicate a modest decrease in mean efavirenz plasma exposure 218 with rifampin coadministration in the subjects as a whole, as well as a wide variability in 219 response. The mean decrease in efavirenz AUC 0-24h of 16% in this crossover study is 220 numerically lower than the 26% reduction reported in a healthy volunteer study (2) and the 24% 221 decrease in Spanish HIV/TB co-infected patients (24). However, the mean decrease in efavirenz 222 AUC 0-24h was significant (P < 0.05) in our and the previous healthy volunteer study (2) but was contrast, other HIV/TB co-infected patients have required increased doses up to 1600 mg daily to 242 achieve desired plasma concentrations and virologic suppression during concurrent therapy (4).
243
The above-mentioned clinical studies or case reports indicate that a better understanding of the 244 individual differences in the efavirenz pharmacokinetic response to rifampin coadministration is 245 necessary for rational decisions about efavirenz dose-adjustment with rifampin therapy, as one 246 dose adjustment will not fit all patients.
12
Nearly one-half of the subjects in this study had efavirenz trough concentrations 248 considered to be sub-therapeutic during the period of rifampin coadministration but only one of 249 the 11 patients had sub-therapeutic trough concentration in the absence of rifampin. Although 250 the minimum effective efavirenz plasma concentration is still controversial, our findings suggest 251 that some but not all individuals are likely under-dosed using the current standard fixed dose.
252
Both CYP2B6 516/983 "fast metabolizers" as well as higher body weight appeared to predict a 516G→T polymorphisms (8, 19, 20, 34, 40) .
257
The main limitation of our study was the small number of subjects with known functional 258 genetic variants. This limited our ability to draw any firm conclusions about lack of association 259 with some of the genetic factors especially for PXR and CAR. We also did not assay for 
